Cholangiocarcinoma With IDH1 Mutation
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Cholangiocarcinoma With IDH1 Mutation trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Cholangiocarcinoma With IDH1 Mutation trials you may qualify forA open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cock…
The objective of this study is to investigate the safety, tolerability and preliminary activity of ivosidenib in combination with durvalumab and gemcitabine/cis…
Cholangiocarcinoma is a rare and aggressive tumor of the bile duct associated with a poor prognosis and very limited treatment options. The IDH1 inhibitor ivosi…
This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydro…
This is a Phase 1/2 study evaluating the safety, tolerability, and activity of ivosidenib in combination with immunotherapy in participants with nonresectable o…